(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 April 2014 (10.04.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/053521 A3

(51) **International Patent Classification**:
A61K 47/48 (2006.01) *A61P 31/04* (2006.01)
A61K 39/095 (2006.01) *A61P 37/04* (2006.01)

(21) **International Application Number**:
PCT/EP2013/070496

(22) **International Filing Date**:
2 October 2013 (02.10.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/709,093 2 October 2012 (02.10.2012) US

(71) **Applicant**: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors**: **BERTI, Francesco**; Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, I-53100 Siena (IT). **BROGIONI, Giulia**; Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, I-53100 Siena (IT). **COSTANTINO, Paolo**; Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, I-53100 Siena (IT). **DEL GIUDICE, Giuseppe**; Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, I-53100 Siena (IT). **ROMANO, Maria**; Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, I-53100 Siena (IT).

(74) **Agents**: **EVANS, Stephen John Eves** et al.; Novartis Vaccines and Diagnostics S.r.l, Via Fiorentina 1, I-53100 Siena (IT).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

[Continued on next page]

(54) **Title**: NONLINEAR SACCHARIDE CONJUGATES




Figure 4

(57) **Abstract**: This specification is directed to nonlinear saccharide conjugates that comprise polysaccharides that are linked to at least two peptides that comprise T-cell epitopes and have no conformational B-cell epitopes where one of the peptides is linked to an internal saccharide so that the conjugates have a branched (i.e., nonlinear) structure. The specification also provides methods of manufacturing these conjugates, methods of formulating these conjugates in compositions for use as vaccines and methods of using the compositions to induce an immune response to the capsular saccharide. The specification also provides a new polyepitope carrier peptidecomprising the PV1 epitope from polio virus. The new polyepitope carrier peptidecan be used in both linear saccharide conjugates as well as the nonlinear saccharide conjugates.

WO 2014/053521 A3

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
17 July 2014